Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 318

Similar articles for PubMed (Select 23290787)

1.

Resistance to BRAF-targeted therapy in melanoma.

Sullivan RJ, Flaherty KT.

Eur J Cancer. 2013 Apr;49(6):1297-304. doi: 10.1016/j.ejca.2012.11.019. Epub 2013 Jan 2. Review.

PMID:
23290787
2.

Trametinib in metastatic melanoma.

Chopra N, Nathan PD.

Expert Rev Anticancer Ther. 2015 Jul;15(7):749-60. doi: 10.1586/14737140.2015.1060127.

PMID:
26107021
3.

[Modern methods of systemic treatment for disseminated melanoma].

Novik AV, Protsenkol SA, Semenova AI, Latipova DKh, A S Zhabina, Akhaeva ZY.

Vopr Onkol. 2015;61(2):297-302. Russian.

PMID:
26087614
4.

[BRAF inhibitor and MEK inhibitor].

Uhara H.

Gan To Kagaku Ryoho. 2015 Apr;42(4):428-33. Japanese. No abstract available.

PMID:
26020982
5.

BRAF Targets in Melanoma. Biological Mechanisms, Resistance, and Drug Delivery.

[No authors listed]

Anticancer Res. 2015 May;35(5):3113. No abstract available.

PMID:
25964616
6.

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.

Queirolo P, Picasso V, Spagnolo F.

Cancer Treat Rev. 2015 Jun;41(6):519-526. doi: 10.1016/j.ctrv.2015.04.010. Epub 2015 Apr 29. Review.

PMID:
25944484
7.

Treatment of BRAF-mutated advanced cutaneous melanoma.

Trinh VA, You Y, Hwu WJ.

Chin Clin Oncol. 2014 Sep;3(3):28. doi: 10.3978/j.issn.2304-3865.2014.05.10.

8.

Therapy-induced tumour secretomes promote resistance and tumour progression.

Obenauf AC, Zou Y, Ji AL, Vanharanta S, Shu W, Shi H, Kong X, Bosenberg MC, Wiesner T, Rosen N, Lo RS, Massagué J.

Nature. 2015 Apr 16;520(7547):368-72. doi: 10.1038/nature14336. Epub 2015 Mar 25.

PMID:
25807485
9.

Discussion.

[No authors listed]

J Am Coll Surg. 2015 Apr;220(4):593-5. doi: 10.1016/j.jamcollsurg.2015.01.025. No abstract available.

PMID:
25797744
10.

Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma.

Johnson AS, Crandall H, Dahlman K, Kelley MC.

J Am Coll Surg. 2015 Apr;220(4):581-93.e1. doi: 10.1016/j.jamcollsurg.2014.12.057. Epub 2015 Jan 30.

PMID:
25797743
11.

[Targeted molecular therapies (except immunotherapy)].

Roux J, Pages C, Lebbé C.

Bull Cancer. 2014 Dec;101 Suppl 2:S25-36. doi: 10.1684/bdc.2014.2053. Review. French.

PMID:
25776764
12.

B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches.

Temraz S, Alameddine R, Shamseddine A.

Curr Opin Oncol. 2015 May;27(3):276-81. doi: 10.1097/CCO.0000000000000184.

PMID:
25774859
13.

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma.

Welsh SJ, Corrie PG.

Ther Adv Med Oncol. 2015 Mar;7(2):122-36. doi: 10.1177/1758834014566428. Review.

14.

Dabrafenib in the treatment of metastatic or unresectable melanoma.

Khoja L, Hogg D.

Expert Rev Anticancer Ther. 2015 Mar;15(3):265-76. doi: 10.1586/14737140.2015.1014343.

PMID:
25711514
15.

Removing a hair of doubt about BRAF targeting.

Kreitman RJ.

Blood. 2015 Feb 19;125(8):1199-200. doi: 10.1182/blood-2014-12-616318.

PMID:
25700421
16.

Targeted therapies: Drug addiction revealed in BRAF and MEK inhibitor-resistant melanoma cells.

Sidaway P.

Nat Rev Clin Oncol. 2015 Apr;12(4):189. doi: 10.1038/nrclinonc.2015.28. Epub 2015 Feb 17. No abstract available.

PMID:
25687909
17.

[Systemic treatment of melanoma brain metastases].

Le Rhun É, Mateus C, Mortier L, Dhermain F, Guillot B, Grob JJ, Lebbe C, Thomas M, Jouary T, Leccia MT, Robert C.

Cancer Radiother. 2015 Feb;19(1):48-54. doi: 10.1016/j.canrad.2014.11.010. Epub 2015 Feb 2. Review. French.

PMID:
25656856
18.

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies.

Spagnolo F, Ghiorzo P, Orgiano L, Pastorino L, Picasso V, Tornari E, Ottaviano V, Queirolo P.

Onco Targets Ther. 2015 Jan 16;8:157-68. doi: 10.2147/OTT.S39096. eCollection 2015. Review.

19.

BRAF and MEK inhibition in melanoma.

Dossett LA, Kudchadkar RR, Zager JS.

Expert Opin Drug Saf. 2015 Apr;14(4):559-70. doi: 10.1517/14740338.2015.1011618. Epub 2015 Feb 4.

PMID:
25648338
20.

Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.

Seremet T, Lienard D, Suppa M, Trepant AL, Rorive S, Woff E, Cuylits N, Jansen Y, Schreuer M, Del Marmol V, Neyns B.

Melanoma Res. 2015 Apr;25(2):180-3. doi: 10.1097/CMR.0000000000000145.

PMID:
25643238
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk